Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
2009 WS
-
2009 SS
- Seminar Geburtshilfe für Blockpraktikanten (PV)
- Frauenheilkunde und Geburtshilfe (WA) (3. Semester des zweiten Studienabschnitte)
- Die senologische Sprechstunde (*)
- Frauenheilkunde und Geburtshilfe (PV)
- Gynäkologisches Seminar für Blockpraktikanten (PV)
- Aktuelle Aspekte gut- u. bösartiger Brusterkrankungen (*)
- Anleitung zum wissenschaftlichen Arbeiten (*)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole : Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerIn: European Journal of Cancer (EJC) Jg. 198 (2024) 113480Online Volltext: dx.doi.org/ (Open Access)
-
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer : 5-Year Survival in the WSG-ADAPT-TP TrialIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 22, S. 3796 - 3804Online Volltext: dx.doi.org/
-
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer : a consensus recommendation from the EORTC Imaging and Breast Cancer GroupsIn: The Lancet Oncology Jg. 24 (2023) Nr. 8, S. e331 - e343Online Volltext: dx.doi.org/
-
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- TrialIn: Clinical Cancer Research Jg. 29 (2023) Nr. 4, S. 805 - 814Online Volltext: dx.doi.org/ (Open Access)
-
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer : results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trialIn: Annals of Oncology Jg. 34 (2023) Nr. 6, S. 531 - 542Online Volltext: dx.doi.org/
-
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrantIn: Trials Jg. 24 (2023) Nr. 1, 338Online Volltext: dx.doi.org/ (Open Access)
-
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer : Update 2022In: Breast Care Jg. 17 (2022) Nr. 4, S. 403 - 420Online Volltext: dx.doi.org/ (Open Access)
-
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022In: Breast Care Jg. 17 (2022) Nr. 4, S. 421 - 429Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
AGO Recommendations for the Surgical Therapy of Breast Cancer : Update 2022In: Geburtshilfe und Frauenheilkunde Jg. 82 (2022) Nr. 10, S. 1031 - 1043Online Volltext: dx.doi.org/ (Open Access)
-
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) : Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialIn: Clinical Cancer Research Jg. 28 (2022) Nr. 22, S. 4995 - 5003Online Volltext: dx.doi.org/
-
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast CancerIn: Journal of Clinical Oncology (JCO) (2022) JCO.21.02759Online Volltext: dx.doi.org/ (Open Access)
-
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialIn: Breast Cancer Research Jg. 24 (2022) Nr. 1, 58Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer : findings from the RIBECCA trialIn: European Journal of Cancer (EJC) Jg. 162 (2022) S. 45 - 55Online Volltext: dx.doi.org/
-
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer : Update 2021In: Breast Care Jg. 16 (2021) Nr. 3, S. 228 - 235Online Volltext: dx.doi.org/ (Open Access)
-
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes : Combined analysis from the WSG ADAPT subtrialsIn: International Journal of Cancer Jg. 148 (2021) Nr. 10, S. 2614 - 2627Online Volltext: dx.doi.org/ (Open Access)
-
Effects of an integrative mind-body-medicine group program on breast cancer patients during chemotherapy : An observational studyIn: Current Pharmaceutical Design Jg. 27 (2021) Nr. 8, S. 1112 - 1120Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of auricular acupuncture for the treatment of insomnia in breast cancer survivors : A randomized controlled trialIn: Cancers Jg. 13 (2021) Nr. 16, 4082Online Volltext: dx.doi.org/ (Open Access)
-
Gynecologists’ attitudes toward and use of complementary and integrative medicine approaches : Results of a national survey in GermanyIn: Archives of Gynecology and Obstetrics Jg. 303 (2021) Nr. 4, S. 967 - 980Online Volltext: dx.doi.org/ (Open Access)
-
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trialIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 5, S. e002198Online Volltext: dx.doi.org/ (Open Access)
-
Immune markers and tumor-related processes predict neoadjuvant therapy response in the wsg-adapt her2-positive/hormone receptor-positive trial in early breast cancerIn: Cancers Jg. 13 (2021) Nr. 19, 4884Online Volltext: dx.doi.org/ (Open Access)
-
Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrialsIn: Breast Cancer Research Jg. 23 (2021) Nr. 1, 36Online Volltext: dx.doi.org/ (Open Access)
-
Mind-Body-Medizin in der Integrativen Onkologie : Studienlage und EinsatzgebieteIn: Der Gynäkologe Jg. 54 (2021) Nr. 1, S. 19 - 25Online Volltext: dx.doi.org/
-
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancerIn: Cancer Medicine Jg. 10 (2021) Nr. 23, S. 8581 - 8594Online Volltext: dx.doi.org/ (Open Access)
-
The INTREST registry : Protocol of a multicenter prospective cohort study of predictors of women’s response to integrative breast cancer treatmentIn: BMC Cancer Jg. 21 (2021) Nr. 1, 724Online Volltext: dx.doi.org/ (Open Access)
-
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrialsIn: The Breast Jg. 59 (2021) S. 58 - 66Online Volltext: dx.doi.org/ (Open Access)
-
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsIn: The Breast Jg. 50 (2020) S. 11 - 18Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer : Primary translational analysis of the WSG-ADAPT-TN trialIn: International Journal of Cancer Jg. 146 (2020) Nr. 1, S. 262 - 271Online Volltext: dx.doi.org/ (Open Access)
-
Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance : WSG-ADAPT HR+/HER2- translational resultsIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S306Online Volltext: dx.doi.org/ (Open Access)
-
Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth systemIn: European Journal of Cancer (EJC) Jg. 138 (2020) S. S68Online Volltext: dx.doi.org/
-
The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancerIn: Therapeutic Advances in Medical Oncology Jg. 12 (2020)Online Volltext: dx.doi.org/ (Open Access)
-
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)In: Clinical Cancer Research Jg. 25 (2019) Nr. 10, S. 2975 - 2987Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)In: Anti-Cancer Drugs Jg. 30 (2019) Nr. 4, S. 394 - 401Online Volltext: dx.doi.org/
-
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerIn: Breast Cancer Research and Treatment Jg. 174 (2019) Nr. 2, S. 453 - 461Online Volltext: dx.doi.org/
-
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients : five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialIn: Breast Cancer Research and Treatment Jg. 175 (2019) Nr. 1, S. 265 - 266Online Volltext: dx.doi.org/ (Open Access)
-
Hypoglossal acupuncture for acute chemotherapy-induced dysgeusia in patients with breast cancer : Study protocol of a randomized, sham-controlled trialIn: Trials Jg. 20 (2019) Nr. 1, S. 398Online Volltext: dx.doi.org/ (Open Access)
-
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84) : A randomised phase III trialIn: European Journal of Cancer (EJC) Jg. 106 (2019) S. 181 - 192Online Volltext: dx.doi.org/
-
Komplementäre Therapien in der OnkologieIn: Der Gynäkologe Jg. 52 (2019) Nr. 2, S. 135 - 143Online Volltext: dx.doi.org/
-
Kurzzeitfasten unter ChemotherapieIn: Geburtshilfe und Frauenheilkunde Jg. 79 (2019) Nr. 9, S. 937 - 939Online Volltext: dx.doi.org/
-
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsIn: International Journal of Cancer Jg. 145 (2019) Nr. 8, S. 2114 - 2121Online Volltext: dx.doi.org/ (Open Access)
-
West German Study PlanB Trial : Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 10, S. 799 - 808Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer : Randomized WSG-ADAPT-TN Trial ResultsIn: Journal of the National Cancer Institute (JNCI) Jg. 110 (2018) Nr. 6, S. 628 - 637Online Volltext: dx.doi.org/ (Open Access)
-
De-escalation strategies in HER2-positive early breast cancer (EBC) : Final analysis of the WSG-ADAPT HER2+/HR- phase II trial: Efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxelIn: Annals of Oncology Jg. 28 (2017) Nr. 11, S. 2768 - 2772Online Volltext: dx.doi.org/
-
Efficacy and safety of nab-paclitaxel 125 mg/m² and nab-paclitaxel 150 mg/m² compared to paclitaxel in early high-risk breast cancer : Results from the neoadjuvant randomized GeparSepto study (GBG 69)In: Breast Cancer Research and Treatment Jg. 163 (2017) Nr. 3, S. 495 - 506Online Volltext: dx.doi.org/
-
Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer : Secondary analysis of the GeparSixto randomized clinical trialIn: JAMA Oncology Jg. 3 (2017) Nr. 10, S. 1378 - 1385Online Volltext: dx.doi.org/ (Open Access)
-
Interest in Integrative Medicine among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyIn: Integrative Cancer Therapies Jg. 16 (2017) Nr. 2, S. 165 - 175Online Volltext: dx.doi.org/ (Open Access)
-
Lebensstilfaktoren und Komplementärmedizin beim MammakarzinomIn: Der Gynäkologe Jg. 50 (2017) Nr. 7, S. 525 - 531Online Volltext: dx.doi.org/
-
Mind-Body-Medizin in der integrativen Onkologie : Studienlage und EinsatzgebieteIn: Der Gynäkologe Jg. 50 (2017) Nr. 1, S. 31 - 35Online Volltext: dx.doi.org/
-
Mindfulness-based interventions for women with breast cancer : an updated systematic review and meta-analysisIn: Acta Oncologica Jg. 56 (2017) Nr. 12, S. 1665 - 1676Online Volltext: dx.doi.org/ (Open Access)
-
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer : A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)In: European Journal of Cancer (EJC) Jg. 85 (2017) S. 133 - 145Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)In: European Journal of Cancer (EJC) Jg. 84 (2017) S. 1 - 8Online Volltext: dx.doi.org/
-
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer : a randomized Phase I studyIn: Breast Cancer Research and Treatment Jg. 162 (2017) Nr. 3, S. 479 - 488Online Volltext: dx.doi.org/ (Open Access)
-
The effects of yoga and self-esteem on menopausal symptoms and quality of life in breast cancer survivors : a secondary analysis of a randomized controlled trialIn: Maturitas: The European Menopause Journal Jg. 105 (2017) S. 95 - 99Online Volltext: dx.doi.org/
-
Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy : Results from the multi-center SENTINA trialIn: The Breast Jg. 31 (2017) S. 202 - 207Online Volltext: dx.doi.org/
-
pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy : A retrospective pooled analysis of individual patients data of four German neoadjuvant trialsIn: The Breast Jg. 32 (2017) S. 73 - 78Online Volltext: dx.doi.org/
-
Yoga and meditation for menopausal symptoms in breast cancer survivors : A randomized controlled trialIn: Cancer Jg. 121 (2015) Nr. 13, S. 2175 - 2184Online Volltext: dx.doi.org/ (Open Access)
-
Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancerIn: Breast Care Jg. 8 (2013) Nr. 1, S. 60 - 66Online Volltext: dx.doi.org/
-
Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancerIn: Acta Radiologica Jg. 52 (2011) Nr. 9, S. 1009 - 1014Online Volltext: dx.doi.org/
-
Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography : Initial resultsIn: The British Journal of Radiology (BJR) Jg. 84 (2011) Nr. 998, S. 126 - 135Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Impact of treatment characteristics on response of different breast cancer phenotypes : Pooled analysis of the German neo-adjuvant chemotherapy trialsIn: Breast Cancer Research and Treatment Jg. 125 (2011) Nr. 1, S. 145 - 156Online Volltext: dx.doi.org/
-
Optimizing the clinical management of gynecological and breast cancer via online tumor conferencesIn: Anticancer Research Jg. 31 (2011) Nr. 8, S. 2669 - 2673
-
Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer : Results of the NOGGO-AGO Intergroup StudyIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 28, S. 3791 - 3797Online Volltext: dx.doi.org/
-
Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer stagingIn: European Journal of Nuclear Medicine & Molecular Imaging Jg. 37 (2010) Nr. 6, S. 1077 - 1086Online Volltext: dx.doi.org/
-
Dynamic Contrast-Enhanced Breast MRI at 7 Tesla Utilizing a Single-loop Coil : A Feasibility TrialIn: Academic Radiology Jg. 17 (2010) Nr. 8, S. 1050 - 1056Online Volltext: dx.doi.org/
-
Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 36 (2009) Nr. 10, S. 1543 - 1550Online Volltext: dx.doi.org/
-
Screening von psychischen Belastungen bei ersterkrankten Brustkrebspatientinnen : Einsatz von HADS-D und PO-BadoIn: Zeitschrift für Psychosomatische Medizin und Psychotherapie Jg. 55 (2009) Nr. 3, S. 248 - 262Online Volltext: dx.doi.org/
-
Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer : WSG ADAPT TP trialIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 1285Online Volltext: dx.doi.org/ (Open Access)
-
LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC) : ADAPT-TP survival resultsIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S1146Online Volltext: dx.doi.org/ (Open Access)